ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

Rush venom immunotherapy: a 3-day programme for hymenoptera sting allergy (1984)

NATAF, P. ; GUINNEPAIN, M. T. ; HERMAN, D.

Oxford, UK : Blackwell Publishing Ltd

Clinical & experimental allergy 14 (1984), S. 0

add to mindlist on the mindlist

Details

ISSN: 1365-2222

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: In a series of 102 patients consulting for allergic reactions following hymenoptera sting, fifty-two of them, who had experienced one or more severe systemic adverse reactions were selected for rush immunotherapy.The method employed made it possible to attain the maintenance dose of 100 μg of venom in 3 days. Patient tolerance was excellent, no serious side-effect was observed; immunotherapy never had to be stopped. Clinical effectiveness seems to be very satisfactory, since no abnormal reaction was reported in seven patients who later were spontaneously stung, and in fourteen patients who received an induced insect sting. The level of IgG antivenom antibodies rose regularly from the first month onwards to remain at a stable level.Because of its safety and effectiveness, it appears that this method should be recommended for immunotherapy in patients who are allergic to hymenoptera stings.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1111/j.1365-2222.1984.tb02206.x

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Pulmonary hypertension and dexfenfluramine (1995)

Cacoub, P. ; Piette, J. C. ; Godeau, P. ; [et al.]

Springer

European journal of clinical pharmacology 48 (1995), S. 81-83

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: Pulmonary hypertension ; Dexfenfluramine ; adverse effects

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Abstract Appetite suppressants, including aminorex and fenfluramine, have been associated with pulmonary hypertension ever since the well-known outbreak of primary pulmonary hypertension in Europe after treatment with aminorex. The usage of a new anorectic agent, dexfenfluramine, has recently increased dramatically in developed countries. We report 2 new cases of lethal pulmonary hypertension associated with the use of dexfenfluramine.